Pamela Morris to Anticholesteremic Agents
This is a "connection" page, showing publications Pamela Morris has written about Anticholesteremic Agents.
Connection Strength
1.409
-
Review of clinical practice guidelines for the management of LDL-related risk. J Am Coll Cardiol. 2014 Jul 15; 64(2):196-206.
Score: 0.464
-
2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022 10 04; 80(14):1366-1418.
Score: 0.203
-
Very High-Risk ASCVD and Eligibility for Nonstatin Therapies Based on the 2018?AHA/ACC Cholesterol Guidelines. J Am Coll Cardiol. 2019 08 06; 74(5):712-714.
Score: 0.165
-
Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial. Circulation. 2019 01 15; 139(3):410-412.
Score: 0.158
-
Optimizing Cholesterol Treatment in Patients With Muscle Complaints. J Am Coll Cardiol. 2017 Sep 05; 70(10):1290-1301.
Score: 0.144
-
2017 Focused Update of the 2016?ACC?Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in?the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2017 Oct 03; 70(14):1785-1822.
Score: 0.144
-
2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2016 07 05; 68(1):92-125.
Score: 0.131